SUPPLEMENTARY MATERIAL

Supplementary Table. Studies about the prevalence of non-asthmatic eosinophilic bronchitis and the diagnostic criteria used in each one.

	Recruitment place and time	Patients included	Diagnostic criteria	Number of NAEB (%)
Asia				
Joo JH et al. 2002 (8)	Korea 1998-1999	92	Cough > 3w, >3% sputum eos., negative methacholine inhalation challenge and no PEFR variation	11 (12%)
Kwon NH et al. 2006 (101)	Korea 2001-2003	184	Cough lasting 3 to 8w and >3% sputum eos.	10 (5.4%)
Wei W et al. 2009 (4)	China 2005-2007	287	Cough > 8w, >3% sputum eos., and the relief of cough with corticosteroid therapy	< 60 years: 25 (13.7%) ≥ 60 years: 8 (7.7%)
Lai K et al. 2013 (5)	China 2009 -2010	640	Cough >8w and >2.5% sputum eos.	131(17.2%)
Yu L et al. 2011 (102)	China 2009 - 2010	109	Cough > 8w and > 2,5% sputum eos. responsive to corticosteroids	7 (6.4%)
Australia				
Carney IK et al. 1997 (6)	Australia 1995	30	Cough > 4w, sputum eosinophilia (value not defined), normal spirometry and normal chest X-ray	3 (10%)
Europe				
Brightling CE et al. 1999 (9)	United Kingdom 1996 - 1997	91	Cough > 3w, > 3% sputum eos. and negative methacholine inhalation challenge	12 (13.2%)
Ayik SO et al. 2003 (103)	Turkey 2000-2001	36	Cough > 4w, > 3% sputum eos. negative methacholine inhalation challenge, normal spirometry	12 (33.3%)
Birring S et al. 2009 (48)	United Kingdom 2000-2001	236	Cough > 3w, > 3% sputum eos., negative methacholine inhalation challenge, normal spirometry, normal PEF variability normal chest radiograph	17 (7%)
Dąbrowska M et al. 2014 (104)	Poland 2007-2009	129	Cough >8w, >3% sputum eos. and negative methacholine inhalation challenge	9 (7%)
Dąbrowska M, et al. 2015 (105)	Poland 2009-2011	127	Cough >8w, >3% sputum eos. and negative methacholine inhalation challenge	19 (15%)
America				
Ribeiro M et al. 2006 (106)	Brasil 2004-2005	147	Cough >8w, >3% sputum eos. and negative methacholine inhalation challenge	15 (10%)

Footnote: negative methacholine inhalation challenge was considered when $PC_{20}FEV_1 > 16$ mg/ml; PEF: peak expiratory flow; PEFR: peak expiratory flow rate; eos: eosinophils; w: weeks

J Investig Allergol Clin Immunol 2024; Vol 34(5) : 282-292 doi: 10.18176/jiaci.0984